Pliant Therapeutics Inc. (NASDAQ: PLRX) presented updated results from its Phase 1 trial of PLN-101095 combined with pembrolizumab in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE